Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) traded up 6.8% on Tuesday following a better than expected earnings announcement. The stock traded as high as $3.01 and last traded at $3.05.

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

We recently compiled a list of the Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a look at ...

Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...

In the report, ImmunityBio discusses its significant developments, including receiving a J-code for Anktiva in the U.S., ...